ERAS-007

PreclinicalSmall molecule

ERAS-007 is one of 4 small molecule programs targeting Advanced or Metastatic Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorsActive, not recruiting

Advanced or Metastatic Solid TumorsPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

21 2

Vectibix

Amgen

Phase 1

1 3

ERAS-601

EErasca, Inc.

Preclinical

2 4

ERAS-007

EErasca, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Advanced or Metastatic Solid Tumors

NCT04866134

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Withdrawn·EErasca, Inc.·Phase 1/2·NCT05279859

Gastrointestinal1 trial

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Completed·EErasca, Inc.·Phase 1/2·NCT05039177·101 enrolled

Advanced NSCLC1 trial

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed·EErasca, Inc.·Phase 1·NCT04959981·24 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination With ERAS-601 (SHP2 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)

Active, not recruiting·EErasca, Inc.·Preclinical·NCT04866134·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ERAS-007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ERAS-007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ERAS-007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Erasca, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EErasca, Inc.

ERAS-007

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hematologic Malignancies1 trial

Gastrointestinal1 trial

Advanced NSCLC1 trial

Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News